Equity
€203,726 ▲ 44.1%
Equity rose in 2025 from €141,337 to €203,726.
PHARMADIX
Lifetime
3 annual accounts with figures on one time axispeak €133,898 (2023)
€82,674▲ 35.7%
peak €93,020 (2023)
€62,389▲ 62.8%
peak €203,726 (2025)
€203,726▲ 44.1%
€21,743▼ 52.3%
Board2 names since 2022
2 directors and 1 other
Documentsfilings and deeds
22-06-202639 days before the deadline
2025micro format
Gross margin from €60,907 to €82,674Result from €38,317 to €62,389Equity from €141,337 to €203,726Debts from €45,581 to €21,743Cash from €99,380 to €65,397
Key points
from the 2025 annual accountsTurnover
≈ €650,000 estimated
The micro format states no turnover.
Liquidity
10.34 was 3.91 in 2024
Short-term debts fell from €45,581 to €21,002.
Filings
3 annual accounts 1 late
The 2023 accounts came 22 days late. The other two were filed on time.
Starting capital
€10,000 100 shares
Position in the sector
90.4%
Higher solvency than 94% of companies in retail trade. Sector median 33.4% · 25,237 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as PHARMADIX has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for PHARMADIX. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 14-12-2022
Director, since 14-12-2022
- 50 sharesdeed of 20-12-2022
- 50 sharesdeed of 20-12-2022
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0794868478
Incorporation
Founding capital of €10,000, 100 shares · Founders: and · Appointments: (director) and (director) · published on 20-12-2022 · Gazette deed
First establishment
Korteweg 5, Wevelgem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMADIX Wevelgem | €225,469 | €82,674 | 90.4% | - |
| Lily Espace Tervuren | €249,313 | €84,491 | 46.5% | - |
| Panta & Sons Ostend | €163,412 | €75,669 | 20.6% | - |
| Say Cheese Hamme (Vl.) | €260,871 | €62,974 | 6.9% | - |
| SPIJS Ghent | €272,813 | €63,928 | -41.2% | - |
| Boischéri Ixelles | €222,621 | €105,470 | 19.4% | - |
| Paco Belmontes Brussels | €219,645 | €128,711 | 22.7% | - |
These companies have the same main activity as PHARMADIX: other retail sale of food (NACE 47279). They are comparable in size and age: total assets between €163,000 and €273,000, founded between 2021 and 2023.
Official details
Source: KBO- Status
- Active since 16-12-2022Normal situation
- Activity
- Other retail sale of foodNACE 47279
- Establishment unit
- 2.339.263.8768560 Wevelgem, since 16-12-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 28-02-2025
Annual accounts 2025
- €225,469▲ 20.6%
- Filing
- Filed on 22-06-2026, 39 days before the end of the filing period
Insights on PHARMADIX
PHARMADIX files the micro format. That format states no turnover. The gross margin fell from €133,898 in 2023 to €82,674 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMADIX
- What is the company number of PHARMADIX?
- The company number of PHARMADIX is 0794.868.478. The VAT number is the same number with BE in front: BE 0794.868.478.
- Where is PHARMADIX based?
- The registered office is at Korteweg 5, 8560 Wevelgem.Company details
- What does PHARMADIX do?
- According to the KBO register, the main activity is other retail sale of food (NACE 47279).
- What is the legal form of PHARMADIX?
- PHARMADIX is a private limited company (BV).
- When was PHARMADIX founded?
- PHARMADIX was founded on 16-12-2022.
- Is PHARMADIX still active?
- Yes, PHARMADIX is an active enterprise in the KBO register.
- What is the turnover of PHARMADIX?
- The turnover in financial year 2025 is ≈ €650,000. This figure is estimated from the gross margin of €82,674 and 45 comparable companies (NACE 472). It probably lies between €370,000 and €890,000.Financials
- Is PHARMADIX profitable?
- In financial year 2025, PHARMADIX made a profit of €62,389.
- Where can I find the annual accounts of PHARMADIX?
- PHARMADIX filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMADIX due?
- PHARMADIX must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.